Complejo Hospitalario Universitario Insular Materno Infantil — Clinical Trial Site

131 Registered trials

56 Currently recruiting

Organisation

Complejo Hospitalario Universitario Insular Materno Infantil

Location

Las Palmas De Gran Canaria, Spain

Identifier

ORG-100043600

Address

Autovia Del Sur S/n, 35017, Spain

Departments

#034007 Oncologia
#3444: Endocrinología
#5708: Oncology
#ES004:Oncología
Alergology
Allergology
Cardiology
Endocrinologia
Haematology
Hematología
Hematology and Hemotherapy
Hematology Department
Internal medicine- Infectious Disease Department
Medical Oncology
Medical Oncology Department
n/a
Oftalmología
Oncolgy
Oncología
Oncología Médica
Oncology
Oncology Department
Oncology Medicine
Oncology service
Ophthalmology
Pediatric
Pediatric oncology
Pediatric oncology department
Servicio de digestivo
Servicio de Endocrinología y Nutrición
Servicio de Oncologia
Servicio de Oncología médica
Surgery
Urology

Clinical trials at this site (131)

Search interface

This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen… Ended

2023-510015-19-00 Patients with histologically or cytologically documente 5 2019-02-11
Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi… Ended

2024-510967-41-00 Metastatic colorectal cancer 5 2018-09-21
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended

2024-515499-12-00 Acute lymphoblastic leukemia 5 2017-10-02
A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC Ended

2025-522867-13-00 Non Small Cell Lung Cancer 4 2026-04-27
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
A study to evaluate the efficacy, safety, participant choice and preference of an oral once-daily regimen or a long-acting injectable regim… Ended

2023-503893-19-00 HIV-1 infection 5 2023-12-06
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants with Advanced/Metastatic Non-Sq… Ended

2022-500608-23-00 Previously Untreated MET Amplified Locally Advanced/Met 4 2023-04-06
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2… Ended

2024-512590-27-00 Non-resectable locally advanced or metastatic HER2-posi 9 2023-03-08
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended

2023-508528-36-00 Resected squamous cell carcinoma of the head and neck 5 2022-12-16
Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep… Ended

2024-513230-38-00 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, 5 2022-12-15
MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended

2023-503615-14-00 Relapsed or Refractory Classical Hodgkin Lymphoma 4 2022-09-29
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19
A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination… Ended

2024-511744-27-00 Solid tumors, Non-Small Cell Lung Cancer, Cervical Canc 1 2022-06-27
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Fir… Ended

2023-506074-12-00 Metastatic Non-Small Cell Lung Cancer 5 2022-03-22
A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended

2024-513304-33-00 Type 1 diabetes mellitus 5 2022-03-17
A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended

2024-512052-38-00 Advanced triple negative breast cancer 9 2021-12-02
SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS Ended

2024-519633-35-00 Resectable pancreatic adenocarcinoma with risk factors 6 2021-10-25
Phase 2 First-Line ES-SCLC Platform Study Ended

2023-506538-56-00 First-line treatment of participants with extensive-sta 4 2021-08-12
Study of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Given with Chemotherapy, to Treat Metastatic Squamous or Non Squamous … Ended

2023-508308-40-00 Metastatic (stage IV) squamous or nonsquamous non-small 5 2021-07-30
Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung c… Ended

2024-514803-33-00 Non-small cell lung cancer (NSCLC) 4 2021-06-16
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab… Ended

2023-507317-10-00 Locally advanced, unresectable, or metastatic non small 5 2021-05-10
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit… Ended

2023-508443-40-00 Lung Cancer, Non-Small Cell 5 2020-12-18